Patients must not have poorly differentiated neuroendocrine carcinoma, high-grade neuroendocrine carcinoma, adenocarcinoid, goblet cell carcinoid and small cell carcinoma
Have a histologically proven locally advanced or metastatic high grade neuroendocrine carcinoma (NEC)\r\n* Includes small cell and large cell neuroendocrine carcinoma of unknown primary or any extrapulmonary site\r\n* Includes neuroendocrine prostate cancer (de novo or treatment-emergent) of prostate if small cell or large cell histology\r\n* Mixed tumors, e.g. mixed adenoneuroendocrine carcinoma (MANEC) or mixed squamous or acinar cell NEC are allowed if the high grade (small or large cell) NEC component comprises > % of the original sample or subsequent biopsy
Has Merkel cell carcinoma, small cell lung carcinoma, or large cell NEC of lung \r\n* Intermediate grade neuroendocrine tumors are excluded\r\n* Well differentiated grade  neuroendocrine tumors are excluded\r\n* Metastatic high-grade prostate carcinoma with evidence of focal neuroendocrine differentiation on prostate biopsy (e.g., positive chromogranin staining by immunohistochemistry) without small cell or large cell NEC morphology are excluded, as are neuroendocrine prostate cancers with phenotype intermediate between adenocarcinoma and small cell\r\n* Atypical bronchial carcinoid and well differentiated G gastro-entero-pancreatic neuroendocrine tumors (GEP-NET) are excluded
Previously identified small cell neuroendocrine tumours or pure small cell carcinoma of the prostate, based on a prior biopsy of the prostate.
Histologically confirmed prostate cancer; small cell/neuroendocrine differentiated allowed but not required for study participation
Histologically or cytologically confirmed adenocarcinoma of the prostate. No evidence of neuroendocrine differentiation or small cell features.
Histologically confirmed diagnosis of prostate adenocarcinoma; variants of prostate cancer, including neuroendocrine features and small cell carcinoma of the prostate, are not permitted
Poorly differentiated carcinoma, high grade neuroendocrine tumor or small cell carcinomas are excluded from this study
pure small cell, neuroendocrine or other variant (non-adenocarcinoma) prostate cancer histology
Pathology consistent with majority of specimen having small cell carcinoma of the prostate (prostate cancer with neuroendocrine features is acceptable)
Histologic or cytologic diagnosis of adenocarcinoma of the prostate without neuroendocrine differentiation or small cell features
Histologically confirmed prostate adenocarcinoma without neuroendocrine differentiation or small-cell features
Pathologic findings consistent with small-cell or neuroendocrine carcinoma of the prostate
Subjects biopsy specimen reveals neuroendocrine or small cell features
High-Grade Neuroendocrine Carcinoma (HGNEC), any organ of origin, including a pathology of neuroendocrine features, in patients previously been treated with chemotherapy Although neuroendocrine tumors may be classified differently based on organ of origin, in the context of this protocol they are defined as high grade on the basis of either
Histologic features: (a) Neuroendocrine tumors of lung origin are considered high grade if in any part of the tumors, there are > mitoses/mm or  high power field (HPF). Large zones of necrosis are usually present. This includes small cell lung carcinoma and large cell neuroendocrine lung carcinoma. [SCLC will not enroll in the HGNEC cohort.] (b)Neuroendocrine tumors of gastroenteropancreatic origin are considered high grade if in any part of the tumors there are either > mitoses/mm or  high power field (HPF) OR Ki.
Histological or cytological proof of chemotherapy-naive, extensive, small cell lung cancer or neuroendocrine cancers that are either high grade or poorly differentiated
Histologically confirmed metastatic adenocarcinoma of the prostate without histological neuroendocrine differentiation or small cell features
Histological variants in the primary tumor, other than adenocarcinoma; for example: neuroendocrine tumor, small cell or sarcomatoid
Histologic diagnosis of prostate adenocarcinoma\r\n* Pure small cell carcinoma will be excluded; however, component of neuroendocrine /small cell differentiation will be allowed provided that adenocarcinoma constitutes majority of the tissue specimen
Histologically or cytologically confirmed adenocarcinoma of the prostate without neuroendocrine differentiation or small cell features
Histologically confirmed adenocarcinoma of the prostate without signet cell or small cell features
Histologically-confirmed diagnosis of prostate adenocarcinoma; variants of prostate cancer, including neuroendocrine features and small cell carcinoma of the prostate, are not permitted
Metastatic poorly differentiated and/or high-grade neuroendocrine tumor/carcinoma originating outside of the lung (including unknown primary)
Patients must have histologically or cytologically confirmed adenocarcinoma of the prostate with no histological variants (such as small cell, sarcomatoid, pure ductal cancer, transitional cell carcinoma).
Neuroendocrine-like prostate cancer, based on histology OR based on clinical presentation as defined by meeting one of the two below criteria; all subjects must submit their primary tumor or metastatic biopsy pathology specimens to the Duke Cancer Institute where they will be centrally reviewed by Duke Pathology (Dr. Jiaoti Huang); central Duke pathologic review is not required for screening but rather for confirmation of histologic subtype; local pathologic review is sufficient for eligibility determination\r\n* Criterion : presence of  of  histologically proven diagnoses:\r\n** Primary small cell carcinoma of the prostate, defined by classic histologic features such as small tumor cells with scanty cytoplasm, darkly stained nuclei with homogeneous chromatin pattern; the tumor cells do not form glandular structure but grow as solid sheets with frequent mitotic figures and necrosis\r\n** Intermediate atypical carcinoma of the prostate, which has histologic features distinct from small cell carcinoma or adenocarcinoma; the tumor grows as solid sheets or vague glandular structures; the tumor cells have moderate amounts of cytoplasm and centrally located, round and regular nuclei with fine, granular and homogeneous chromatin; mitosis and necrosis are absent\r\n** Mixed histology tumors of the prostate, containing both adenocarcinoma and neuroendocrine or small cell components\r\n* Criterion : presence of histologically proven adenocarcinoma of the prostate without any sign of neuroendocrine or small cell histology that is radiographically progressing despite castrate levels of testosterone (<  ng/mL) with the following poor risk features:\r\n** Prior progression despite therapy with either abiraterone acetate and/or enzalutamide\r\n** At least one of the following:\r\n*** Liver metastases\r\n*** Bulky radiographic progression (>=  cm short axis lymph nodes or >=  cm long axis visceral metastases) combined with low serum PSA (<  ng/mL)\r\n*** High serum LDH (>  X upper limit of normal)
Histological documentation of adenocarcinoma of the prostate reviewed at MD Anderson Cancer Center. Patients with small cell, neuroendocrine, or transitional cell carcinomas are not eligible.
Histologically or cytologically confirmed previously untreated non-small cell lung cancer. If a diagnostic biopsy is available, a pre-treatment biopsy is not required. Patients with a suspected lung cancer are eligible, but pathology must be confirmed prior to initiating treatment on study. Neuroendocrine carcinomas are not eligible. Carcinomas with neuroendocrine differentiation are eligible
Histological confirmation of non-small cell lung cancer (NSCLC) by either biopsy or cytology will be is required for the primary diagnosis and is recommended for recurrent disease. The following primary cancer types are eligible: squamous cell carcinoma, adenocarcinoma (with or without bronchioloalveolar carcinoma features), large cell carcinoma (with or without neuroendocrine features), neuroendocrine carcinoma (either NSCLC with neuroendocrine features or atypical carcinoids, but not small cell lung carcinoma), bronchioloalveolar cell carcinoma, or non-small cell carcinoma not otherwise specified
Progressive castration-resistant metastatic prostate cancer with histologically or cytologically confirmed adenocarcinoma of the prostate without neuroendocrine differentiation or small cell features
Patients with neuroendocrine or small cell features are not eligible
Histologically confirmed diagnosis of prostate cancer; histologic variants of prostate cancer, including neuroendocrine features and small cell carcinoma of the prostate are included; if neuroendocrine prostate cancer is not biopsy proven, clinical evidence of neuroendocrine prostate cancer is acceptable for stratification into group A
Other histologic types of prostate cancers such as ductal, sarcomatous, lymphoma, small cell, and neuroendocrine tumors
Histologic evidence of small cell/neuroendocrine prostate cancer
Small-cell lung cancer/mixed NSCLC with small cell component or other neuroendocrine lung cancers (typical and atypical carcinoids, large-cell neuroendocrine carcinomas). Large-cell carcinoma.
Histologically or cytologically confirmed carcinoma of the prostate (excluding neuroendocrine differentiation or squamous cell histology)
Histologic evidence of neuroendocrine or small cell carcinoma of the prostate
Histologically or cytologically confirmed carcinoma of the prostate (excluding neuroendocrine differentiation or squamous cell histology)
Patients with histologic evidence of small cell carcinoma of the prostate will not be eligible
Prostate cancer with significant sarcomatoid or spindle cell or neuroendocrine small cell components
Patients with histologic evidence of small cell carcinoma of the prostate will not be eligible
Histologically confirmed diagnosis of adenocarcinoma of the prostate; histologic variants of prostate cancer comprising of > % of the tumor including neuroendocrine features and small cell carcinoma of the prostate are excluded
Poorly differentiated or high grade carcinoma, or patients with neuroendocrine tumors not of lung origin are excluded
Histologically confirmed adenocarcinoma of the prostate without morphologic neuroendocrine differentiation or small cell features.
Patients with neuroendocrine or small cell carcinoma of the prostate
Subjects with neuroendocrine and/or small cell CRPC
Well-differentiated grade  neuroendocrine tumors; poorly-differentiated neuroendocrine carcinoma of any origin (other than GEP-NEC); including NEC of unknown origin, adenocarcinoid, and goblet cell carcinoid
Pathology consistent with majority of specimen having small cell carcinoma of the prostate (prostate cancer with other neuroendocrine features is acceptable)
Patients must have histologically or cytologically confirmed neuroendocrine carcinoma of the gastrointestinal (GI) tract; patients with unknown origin for the neuroendocrine carcinoma in which a gastroenteropancreatic origin is suspected (per pathologist or investigator discretion) will be eligible for the study
History of small-cell or neuroendocrine prostate carcinoma
Histologically or cytologically confirmed adenocarcinoma of the prostate at initial biopsy, without neuroendocrine differentiation, signet cell, or small cell features;
Histologically or cytologically confirmed prostate cancer (individuals with primary neuroendocrine carcinoma of prostate are excluded)
Neuroendocrine tumors
Subject is diagnosed with histologically or cytologically confirmed adenocarcinoma of the prostate without neuroendocrine differentiation, signet cell or small cell histology.
Histologically or cytologically confirmed adenocarcinoma of prostate without neuroendocrine differentiation or small cell features.
Histologically or cytologically confirmed adenocarcinoma of the prostate without neuroendocrine differentiation, signet cell, or small cell features;
Patients with neuroendocrine or small cell features are not eligible
Poorly differentiated neuroendocrine carcinoma, high-grade neuroendocrine carcinoma, adenocarcinoid, goblet cell carcinoma, or small cell carcinoma
Neuroendocrine tumors, pancreatic basket:\r\n* Grade , poorly differentiated neuroendocrine carcinoma\r\n* Large cell or small cell histology
Neuroendocrine tumors, extrapancreatic basket:\r\n* Grade , poorly differentiated neuroendocrine carcinoma\r\n* Large cell or small cell histology
Any neuroendocrine differentiation including small cell carcinoma on histology or cytology.
Neuroendocrine (carcinoid, islet cell) or acinar pancreatic carcinoma
Patients with well-differentiated neuroendocrine carcinoma (carcinoid tumor)
Histologically or cytologically confirmed non-small cell lung cancer; patients with a suspected lung cancer are eligible, but pathology must be confirmed prior to initiating treatment on study; neuroendocrine carcinomas are not eligible; carcinomas with neuroendocrine differentiation are eligible
Patients with small cell or neuroendocrine tumours.
Presence of islet-cell or pancreatic neuroendocrine tumor or mixed adenocarcinoma-neuroendocrine carcinoma
Tumors must be histologically or cytologically proven and considered low or intermediate grade; patients with high grade neuroendocrine carcinomas or small cell carcinomas are excluded from the study
High grade NET or small cell neuroendocrine carcinoma
Prostate cancer with significant sarcomatoid or spindle cell or neuroendocrine small cell components
Histologically or cytologically confirmed low or intermediate grade, unresectable well differentiated foregut neuroendocrine tumors (thymic, bronchopulmonary, gastric, duodenal and pancreatic); patients with multiple neuroendocrine tumors associated with MEN syndrome will be eligible
Histologically or cytologically confirmed adenocarcinoma of the prostate without neuroendocrine differentiation, or signet cell or small cell features;
Histologically confirmed adenocarcinoma of the prostate without histological variants (including overt neuroendocrine differentiation, small cell neuroendocrine carcinoma features, sarcomatoid features, pure ductal adenocarcinoma, squamous or transitional cell carcinoma)
Small cell or neuroendocrine carcinoma of the prostate
Participants must have histologically or cytologically confirmed adenocarcinoma of the prostate without > % neuroendocrine differentiation or small cell histology
Progressive castration-resistant metastatic prostate cancer with histologically or cytologically confirmed adenocarcinoma of the prostate without neuroendocrine differentiation or small cell features
Histologically or cytologically confirmed adenocarcinoma of the prostate without neuroendocrine differentiation or small cell features with high risk for development of metastases, defined as prostate-specific antigen doubling time (PSADT) less than or equal to (<=)  months. PSADT is calculated using at least  prostate-specific antigen (PSA) values obtained during continuous ADT (androgen deprivation therapy)
Participants must have histologically or cytologically confirmed adenocarcinoma of the prostate without >= % neuroendocrine differentiation or small cell histology
Histologically confirmed diagnosis of adenocarcinoma of the prostate; histologic variants of prostate cancer, including neuroendocrine features and small cell carcinoma of the prostate are excluded
Low- or intermediate-grade neuroendocrine carcinoma, including the following subtypes: carcinoid tumor, low- to intermediate-grade or well- to moderately-differentiated neuroendocrine carcinoma or tumor, atypical carcinoid tumor; documentation from a primary tumor or metastatic site is sufficient; patients with poorly differentiated neuroendocrine carcinoma, high-grade neuroendocrine carcinoma, adenocarcinoid tumor, or goblet cell carcinoid tumor are not eligible
Patient must have histologically or pathologically confirmed locally unresectable or metastatic low or intermediate grade pancreatic neuroendocrine tumor, excluding small cell carcinoma
Diagnosis of prostate cancer with neuroendocrine differentiation
Poorly differentiated neuroendocrine carcinoma or small cell carcinoma
Small cell carcinoma of the prostate
Patient must have a histologically or cytologically confirmed diagnosis of pancreatic cancer or poorly differentiated neuroendocrine tumor and must have been treated with a regimen with known benefit for pancreatic cancer/poorly differentiated neuroendocrine tumor (MTD expansion cohort only)
Poorly differentiated or high grade pancreatic neuroendocrine tumors
Locally unresectable or metastatic, histologically-confirmed, carcinoid or pancreatic neuroendocrine tumor; tumors must be considered well- or moderately-differentiated; patients with poorly differentiated neuroendocrine carcinoma are excluded from the study
High grade or poorly differentiated neuroendocrine tumors
Histologically confirmed adenocarcinoma of the prostate without neuroendocrine differentiation or small cell features
Expansion Cohort : Subjects with metastatic CRPC (adenocarcinoma of the prostate without neuroendocrine differentiation or small cell features) who have radiographically progressed in soft tissue on or after enzalutamide and/or abiraterone acetate for metastatic disease.
Histologic documentation of prostatic adenocarcinoma; patients with small cell, neuroendocrine, or transitional cell carcinomas are not eligible; all eligible patients must have a known Gleason sum based on biopsy or transurethral resection of the prostate (TURP) at the time of registration
Histologically or cytologically confirmed adenocarcinoma of the prostate without neuroendocrine differentiation or small cell features
Known or suspected neuroendocrine/small cell feature.
Pure small cell carcinoma of the prostate or any mixed histology cancer of the prostate (eg: neuroendocrine) that contains < % adenocarcinoma, as observed on biopsy obtained at the time of diagnosis or on any subsequent biopsies
Histological features of neuroendocrine or bronchioalveolar differentiation.
Histologically or cytologically confirmed carcinoma of the bladder of all histologies except neuroendocrine differentiation or squamous cell histology
Histologic diagnosis of small cell or neuroendocrine prostate cancer
Prior pathology consistent with small cell carcinoma or prostate cancer with predominantly neuroendocrine differentiation
Patients with histologic evidence of small cell carcinoma of the prostate will not be eligible
Histologically or cytologically confirmed adenocarcinoma of the prostate without neuroendocrine differentiation or small cell features
Diagnosis of high-grade (WHO Grade ) or poorly differentiated NET; high-grade neuroendocrine carcinoma; large cell neuroendocrine carcinoma, small cell carcinoma, or mixed small and large cell carcinoma.
Patients with histologic evidence of small cell carcinoma of the prostate will not be eligible
Small cell carcinoma of the prostate
Neuroendocrine prostate cancer.
The participant has well-differentiated or moderately-differentiated, histologically confirmed neuroendocrine carcinoma, including carcinoid of any location and islet cell tumors
Histological documentation of adenocarcinoma of the prostate reviewed at MD Anderson Cancer Center; patients with small cell, neuroendocrine, or transitional cell carcinomas are not eligible
Histologically confirmed adenocarcinoma of the prostate without histological variants comprising > % of the sample as determined by academic center central review (including neuroendocrine differentiation, small cell, sarcomatoid, ductal adenocarcinoma, squamous or transitional cell carcinoma)
Neuroendocrine cancer
Men with small cell neuroendocrine tumors or features of small cell disease
Patients with islet cell/neuroendocrine or papillary cystic neoplasm
Have small cell carcinoma or neuroendocrine component > %
Pure small cell carcinoma of the prostate
Histologically or cytologically confirmed small cell carcinoma, squamous cell carcinoma or adenocarcinoma (confirmed at Memorial Sloan Kettering Cancer Center [MSKCC]) of the bladder, ureter, urethra, urachus, or renal pelvis; patients with squamous cell carcinoma and adenocarcinoma are required to have a predominant squamous or adenocarcinoma component as reviewed by the pathologist at MSKCC; however, if any element of small cell or neuroendocrine differentiation is present, the patients will be classified as small cell/neuroendocrine
Patients with small cell/neuroendocrine cervical carcinoma
Histologically confirmed diagnosis of adenocarcinoma of the prostate; small cell or neuroendocrine tumors of the prostate are also permitted
Histologically confirmed adenocarcinoma of the prostate; patients with small cell, neuroendocrine, and transitional cell carcinomas are not eligible
Histologically or cytologically confirmed adenocarcinoma of the prostate without neuroendocrine differentiation or small cell histology
Histologic evidence of small cell prostate cancer or neuroendocrine differentiation in > % of biopsy tissue
History of neuroendocrine variants of prostate cancer, including small cell carcinoma of the prostate
Patients with poorly differentiated pancreatic neuroendocrine tumors (according to WHO  classification).